A New Peptides International Publication on the Synthesis of Bestatin

Bestatin, or Ubenimex, is an inhibitor of aminopeptidases, leucine aminopeptidase 3 (LAP3), and a potent, irreversible inhibitor of leukotriene A4 (LTA4) hydrolase.1 Like leupeptin, it was first discovered in culture filtrates of the actinomycetes bacteria.2 As leaders in peptide synthesis, scientists at Peptides International have recently published a new article in the Journal of Peptide Science, entitled, “A Practical Diastereoselective Synthesis of (−)‚ÄźBestatin”. While some synthetic methods of bestatin require expensive chiral catalysts or auxiliaries, we report an 8-step, scalable synthesis starting from Boc-D-Phe-OH.3



You can access the full article here: https://onlinelibrary.wiley.com/doi/full/10.1002/psc.3067

For more on bestatin, click here to take a look at our past product spotlight.


  1. L. Örning, G. Krivi, & F.A. Fitzpatrick, The Journal of Biological Chemistry, 266,1375 (1991).
  2. H. Umezawa, et al., Antibiotics, 29(1), 97 (1976).
  3. S. Shang, A.V. Willems, & S.S. Chauhan, Journal of Peptide Science, 24, e3067 (2018).
Industry News , Enzyme Inhibitors & Substrates , Peptides International News

Denise Karounos

See all articles from Denise Karounos

Denise Karounos joined Peptides International in October 2016. After completing her BS in chemistry from West Virginia University, she spent time as an organic chemist at Bachem Bioscience synthesizing peptides and amino acid derivatives. Denise has experience with both solid and solution-phase peptide synthesis, and has worked under both research and cGMP settings. After completion of her MBA at Saint Joseph’s University, Denise transitioned into product management of peptides and amino acid derivatives. Denise has spent her time at PI focusing on both sales and marketing, including quoting, product management, market research and sales analysis, generating technical marketing content, and attending industry conferences.